Briefing
Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.
The primary endpoint was met: partial response in 8/27 (ORR 30%, 95% CI 12-47%). Disease control (PR plus SD lasting more than 4 months) was 59%. Median PFS was 16 weeks. This is metastatic anti-EGFR rechallenge guided by ctDNA resistance mutations, not adjuvant MRD.
- n: 52 screened by liquid biopsy; 36 (69%) negative for RAS/BRAF/EGFR mutations; 27 enrolled and treated
- Assay: ctDNA genotyping for RAS/BRAF/EGFR mutations (assay brand not named in the extracted results)